Hyperion DeFi (NASDAQ:HYPD) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Hyperion DeFi (NASDAQ:HYPD) to a hold rating in a report issued on Monday,Zacks.com reports.

A number of other research firms have also issued reports on HYPD. Wall Street Zen upgraded Hyperion DeFi from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperion DeFi in a research report on Wednesday, October 8th. Cantor Fitzgerald began coverage on shares of Hyperion DeFi in a research report on Tuesday, December 16th. They set an “overweight” rating and a $4.00 target price on the stock. Finally, Chardan Capital set a $7.75 target price on shares of Hyperion DeFi and gave the company a “buy” rating in a research note on Wednesday, December 24th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $4.58.

Hyperion DeFi Price Performance

HYPD opened at $3.37 on Monday. Hyperion DeFi has a 52-week low of $0.85 and a 52-week high of $17.99. The company has a 50 day moving average of $4.79 and a two-hundred day moving average of $7.60. The company has a market cap of $27.54 million, a P/E ratio of -0.83 and a beta of 2.80. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 0.11.

Hyperion DeFi (NASDAQ:HYPD) last posted its earnings results on Friday, November 14th. The company reported $0.05 earnings per share for the quarter. Hyperion DeFi had a negative net margin of 62,238.41% and a negative return on equity of 119.59%. The business had revenue of $0.36 million for the quarter. On average, analysts expect that Hyperion DeFi will post -41.6 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Happy David Walters purchased 61,930 shares of Hyperion DeFi stock in a transaction dated Wednesday, December 17th. The shares were acquired at an average price of $3.02 per share, with a total value of $187,028.60. Following the completion of the transaction, the director owned 111,930 shares of the company’s stock, valued at approximately $338,028.60. This trade represents a 123.86% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael S. Geltzeiler purchased 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The stock was purchased at an average price of $3.01 per share, with a total value of $90,300.00. Following the completion of the purchase, the director directly owned 88,015 shares of the company’s stock, valued at approximately $264,925.15. This represents a 51.71% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 161,254 shares of company stock valued at $511,126 in the last ninety days. Corporate insiders own 10.86% of the company’s stock.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.